Epoetin alfa: patient management issues and development through recombinant DNA technology. Part 1: Focus on Epoetin alfa patient management and recombinant DNA technology.
The emergence of the Epoetin alfa as an effective therapy in the treatment of the anemia of chronic renal failure has reemphasized the importance of nursing monitoring and intervention in the treatment of these patients. This article examines the role of nurses in monitoring and managing patients receiving Epoetin alfa and the development of medications, such as Epoetin alfa, with recombinant DNA technology.
D
D
Latham
E
E
Nichols
D000747:Anemia, Hypochromic / Q000188:drug therapy / Q000209:etiology / Q000451:nursing; D004274:DNA, Recombinant / Q000627:therapeutic use*; D004921:Erythropoietin / Q000627:therapeutic use*; D006801:Humans; D007676:Kidney Failure, Chronic / Q000150:complications / Q000451:nursing; D011994:Recombinant Proteins / Q000627:therapeutic use; D006435:Renal Dialysis / Q000009:adverse effects / Q000451:nursing
D004274:DNA, Recombinant; D011994:Recombinant Proteins; D004921:Erythropoietin